IMO-3100, an antagonist of Toll-like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a phase 2a trial

Category Primary study
ConferenceJournal of Investigative Dermatology
Year 2013
This article has no abstract
Epistemonikos ID: 18b412203c3a4e101fd8c2ae1ad68ab2e28d00e7
First added on: Apr 30, 2026